Kezar Life Sciences Inc - Asset Resilience Ratio
Kezar Life Sciences Inc (KZR) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Kezar Life Sciences Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Kezar Life Sciences Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Kezar Life Sciences Inc total assets.
Liquid Assets Composition Over Time
This chart breaks down Kezar Life Sciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Kezar Life Sciences Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Kezar Life Sciences Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Kezar Life Sciences Inc Industry Peers by Asset Resilience Ratio
Compare Kezar Life Sciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Enliven Therapeutics Inc.
NASDAQ:ELVN |
Biotechnology | 83.46% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.12% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
Annual Asset Resilience Ratio for Kezar Life Sciences Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Kezar Life Sciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $76.65 Million | -- |
| 2024-12-31 | 62.55% | $90.50 Million | $144.68 Million | -12.43pp |
| 2023-12-31 | 74.98% | $165.88 Million | $221.24 Million | -3.84pp |
| 2022-12-31 | 78.82% | $236.10 Million | $299.57 Million | +12.06pp |
| 2021-12-31 | 66.75% | $145.47 Million | $217.93 Million | -11.76pp |
| 2020-12-31 | 78.52% | $119.22 Million | $151.84 Million | +7.85pp |
| 2019-12-31 | 70.67% | $63.26 Million | $89.51 Million | -1.93pp |
| 2018-12-31 | 72.59% | $83.25 Million | $114.68 Million | -- |
About Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyo… Read more